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Being quick often comes at the expense of being accurate.This speed–accuracy tradeoff is a
central feature of many types of decision making. It has been proposed that dopamine plays
an important role in adjusting responses between fast and accurate behavior. In the current
study we investigated the role of dopamine in perceptual decision making in humans, focus-
ing on speed–accuracy tradeoff. Using a cued version of the random dot motion task, we
instructed subjects to either make a fast or an accurate decision. We investigated decision
making behavior in subjects who were given bromocriptine (a dopamine receptor agonist)
or placebo. We analyzed the behavioral data using two accumulator models, the drift dif-
fusion model, and the linear ballistic accumulator model. On a behavioral level, there were
clear differences in decision threshold between speed and accuracy focus, but decision
threshold did not differ between the drug and placebo sessions. Bayesian analyses support
the null hypothesis that there is no effect of bromocriptine on decision threshold. On the
neural level, we replicate previous findings that the striatum and pre-supplementary motor
area are active when preparing for speed, compared with accurate decisions. We do not
find an effect of bromocriptine on this activation.Therefore, we conclude that bromocriptine
does not alter speed–accuracy tradeoff.
Keywords: dopamine, speed–accuracy tradeoff, striatum, bromocriptine, functional magnetic resonance imaging,
drift diffusion model, linear ballistic accumulator, model-based neuroimaging
INTRODUCTION
Decision making is an essential aspect of everyday life, and the
ability to make choices based on available information is a critical
function of the brain. One important aspect of making a decision
is the speed–accuracy tradeoff (SAT; Wickelgren, 1977): making
a decision quickly comes at the expense of being accurate, and
vice versa.
To better understand the underlying processes that generate
a decision, several accumulator models of decision making have
been formulated. Such models provide a more thorough analy-
sis of decisions than summary statistics, as they explain the entire
reaction time distribution of both correct and incorrect responses.
These models use several parameters to describe how a decision
takes place, and the values for these parameters can be estimated to
best explain the behavioral pattern. The prototypical accumulator
model is the drift diffusion model (DDM; Ratcliff, 1978), while the
Linear Ballistic Accumulator model (LBA; Brown and Heathcote,
2008) is also commonly used. While there are some differences
between the two models, the conclusions drawn by these models
are largely comparable (Donkin et al., 2011). The DDM explains a
decision using information accumulating from a baseline starting
point between an upper and a lower threshold (see Figure 1). The
distance between the starting point and each threshold represents
the amount of information needed to commit to the different
response alternatives. As evidence favoring one alternative is col-
lected, the signal accumulates toward the corresponding threshold.
When the decision process reaches a threshold, the decision is
made. The critical parameter that determines whether the deci-
sion emphasizes speed or accuracy is the height of the decision
threshold (Ratcliff and Rouder, 1998). A high threshold results in
few errors, but slow reactions, whereas a low threshold results in
more errors, but faster reactions. The difficulty of the task and the
perceptual abilities of the subject are reflected in the drift parame-
ter. An easy task will have a higher drift rate than a hard one, while
subjects who are skilled at the task will have higher drift rates than
subjects who are not (Ratcliff and McKoon, 2008).
Because of the importance of decision making in cognition,
how the brain makes decisions is of great interest to cognitive neu-
roscience. As such, the neural representation of the parameters that
make up a decision has been addressed in many experiments (for
reviews, see Gold and Shadlen, 2007; Heekeren et al., 2008; Bogacz
et al., 2010). One candidate network to implement the decision
threshold is the basal ganglia (BG). The BG are known to play a
central role in action selection. According to a common theory, the
BG, and more specifically the striatum, select one motor program
from a set of competing programs by focally releasing a globally
applied inhibition (Mink, 1996). This mechanism makes the BG a
likely neural correlate of the SAT element of decision making, by
flexibly setting the level of the decision threshold (Lo and Wang,
2006). Recently, research in humans has revealed a frontostriatal
network to be associated with speeded responding (Van Veen et al.,
2008; Forstmann et al., 2010; Van Maanen et al., 2011; see Bogacz
www.frontiersin.org August 2012 | Volume 6 | Article 126 | 1
Winkel et al. Bromocriptine does not alter speed–accuracy tradeoff
decision threshold 
time
stimulus 
onset
response
starting
point
correct
incorrect
sensory evidence
per time unit (drift rate)
FIGURE 1 |The Drift Diffusion Model. Schematic illustration of the main
components of the Drift Diffusion Model, showing a sample path for trial
where a correct decision is made. Figure adapted from Mulder et al. (2012).
et al., 2010 for a review). Two such studies, using the random
dot motion task, showed increased activation in the striatum and
pre-supplementary motor area (pre-SMA) when preparing for fast
vs. accurate decisions (Forstmann et al., 2008; Van Maanen et al.,
2011). Another study manipulated SAT while subjects performed
the Simon task (Van Veen et al., 2008). In preparation for fast vs.
accurate decisions, the authors find increased sustained baseline
activity in a number of regions including the pre-SMA, the stria-
tum, and the intraparietal sulcus (IPS). This sustained baseline
activity is associated with reduced transient, event-related activity
in the same areas, consistent with the notion that an increased base-
line activity requires less additional activation to reach a decision
threshold.
One way that the lowering of the threshold might take place is
through modulation of striatal neurons by dopamine. Although
dopamine is most commonly associated with reward processing,
there is a growing body of evidence indicating that dopamine is
involved in other aspects of cognition. A neural network model
of the cortex and the BG looks into the mechanism for adapting
response thresholds during SAT (Lo and Wang, 2006). This model
proposes that the strength of corticostriatal synapses determines
the height of the decision threshold, setting the level of cortical
activation that is required to achieve a response. As the level of
corticostriatal connectivity is affected by dopaminergic innerva-
tion, this model would predict an important role for dopamine in
SAT. Aside from influencing synaptic plasticity in the longer term,
dopamine also acts as an immediate neuromodulator, changing the
responsivity of striatal neurons on a shorter timeframe. This would
suggest that fluctuations in dopamine should result in changes in
decision threshold. Other research points toward a similar role
for dopamine. Some authors have proposed that dopamine affects
behavioral activation (Robbins and Everitt, 2007), while a model
of behavioral choice suggests that the tonic level of dopamine acts
as a general indicator of response vigor (Niv et al., 2006). Also
consistent with a dopaminergic hypothesis of SAT is the finding
that ADHD patients have a deficit in setting their decision thresh-
old (Mulder et al., 2010), while the dopamine system is known
to be involved in the neuropathology of ADHD (cf. Genro et al.,
2008). In a similar vein, patients with Parkinson’s disease have
more difficulty making fast responses than healthy controls in both
interference (Wylie et al., 2009) and limb movement (Mazzoni
and Hristova, 2007) tasks. Based on these findings, we hypothe-
size that dopamine regulates SAT by increasing striatal excitability,
thus lowering the decision threshold.
In the present study, we examine the frontostriatal speed related
network using fMRI. We first confirm our previous hypothesis that
the striatum and the pre-SMA are involved in setting a threshold
for perceptual decision making. Thus, we replicate the finding
that the striatum and pre-SMA show increased activation while
preparing for fast vs. accurate decisions. Second, we test our main
hypothesis that dopamine regulates the decision threshold. We
manipulate the dopaminergic system through the partially selec-
tive D2/D1 dopamine receptor agonist bromocriptine. This results
in deactivation of neurons expressing D2 receptors, such as in the
indirect pathway, and to a lesser extent in activation of neurons
expressing D1 receptors, such as in the direct pathway. We expect to
see changed decision thresholds under bromocriptine, possibly as
a function of individual differences in working memory capacity
(Kimberg et al., 1997; Cools et al., 2008) or impulsiveness (Cools
et al., 2007). We expect to find that the differences in threshold will
be accompanied by altered activation in the previously described
frontostriatal speed related network in the brain (Forstmann et al.,
2008).
MATERIALS AND METHODS
SUBJECTS
Twenty subjects (10 female, age µ= 23.6, σ= 4.3) were recruited
from the Nijmegen student population. All subjects gave written
informed consent and were compensated for participation. The
study was approved by the local ethics committee (committee for
the protection of human subjects of the Arnhem/Nijmegen region;
CMO protocol number 2008/078).
PROCEDURE
The experiment took place over the course of three sessions. Dur-
ing the intake session, participants were screened by a medical
doctor. This screening included a Mini-International Neuropsy-
chiatric Interview to exclude (a history of) psychiatric diseases
(Sheehan et al., 1998). Additionally, an anamnesis and physical
examination (weight, heart rate, blood pressure, and electrocar-
diogram) were completed to exclude relevant medical history, sub-
stance abuse, or a family history of psychiatric diseases. Self-report
questionnaires and neuropsychological tests were administered to
assess personality traits, IQ, and baseline working memory capac-
ity. All scores were within normal range. Finally, the SAT task was
practiced in the MRI scanner during acquisition of the structural
scans. Subjects were instructed not to use any drugs in the week
prior to the experimental sessions, and not to consume any alcohol
24 h prior to either session.
The second and third sessions were performed identically to
each other, except that the subject received a placebo in one session
and bromocriptine (Parlodel®, Novartis, 1.25 mg) in the other.
This dose was selected based on previous and similar studies,
revealing good tolerance (Gibbs and D’Esposito, 2005; Cools et al.,
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2009; Van der Schaaf et al., in preparation, Van Schouwenburg et
al., in submission). The order of drug application was determined
in a double-blind counterbalanced manner. This counterbalancing
was performed separately for men and women.
During the second and third sessions, subjects ingested their
capsule (bromocriptine or placebo) with a glass of milk at 1.50
p.m. They were asked to wait in an emotionally neutral environ-
ment until being escorted to the scanner. The SAT experiment
was performed during fMRI acquisition from 3.30 p.m. onward.
After this, the subject filled out several state questionnaires and
performed another behavioral experiment, which will be reported
in a separate paper. These questionnaires were the State Anxiety
Inventory (Spielberger et al., 1970; Van der Ploeg et al., 1980),
the Barratt Impulsiveness Scale (Patton et al., 1995), the Behav-
ioral Inhibition/Behavioral Activation Scale (BIS/BAS; Carver and
White, 1994), and the Positive and Negative Affect Scale (Wat-
son et al., 1988). Background neuropsychological tests assessed at
the end of each session day included the digit span test (Groth-
Marnat, 1997), a paper and pencil block completion and number
cancelation test, and a letter fluency test.
EXPERIMENTAL PARADIGM
Subjects performed a random dot motion task in which a cue indi-
cated a trial’s speed or accuracy focus (Forstmann et al., 2008).
Subjects responded to a random dot motion stimulus with a
left or right hand button press, and were instructed to perform
each trial either quickly or accurately depending on the cue. Dur-
ing both sessions, the task comprised two blocks of 105 trials,
each consisting of 50 speed, 50 accuracy, and five dummy trials.
Every trial onset was locked to each fifth scanner pulse, result-
ing in a 10 s trial length, regardless of the trial’s RT. All trials
started with a fixation cross, presented for 500 ms, followed by
a jittered interval (with a duration of 0, 500, 1000, or 1500 ms).
After that interval, a cue was presented for 4800 ms. The cue
could be either SN for speed focus, or AC for accuracy focus.
The cue was followed by a second jittered interval, the length
of which compensated for the first jitter so that the sum of
the two intervals was always 1500 ms. Next was the random dot
motion stimulus with a coherence of 50%, which was presented
for 1500 ms, or until a response was made. After a 300 ms delay,
the subjects were presented with feedback for 350 ms. For the
accuracy trials this feedback could be either “correct” or “incor-
rect.” For the speed trials this feedback could be either “in time”
(when subjects responded before 400 ms) or “too late” (when sub-
jects responded between 400 and 1000 ms). If the subject did
not respond within the first 1000 ms of the stimulus, the sub-
ject received a feedback stating “no response.” Following feedback
presentation, no more stimuli were presented until the start of the
next trial. During the dummy trials, a fixation cross was presented
for 10 s.
BAYESIAN T -TESTS
In several statistical analyses, we report Bayesian posterior prob-
abilities in addition to conventional p-values to support the null
hypothesis that the behavior during drug and placebo was the
same. When we assume, for fairness, that the null hypothe-
sis and the alternative hypothesis are equally plausible a priori,
a default Bayesian t -test (Wetzels et al., 2009) allows one to
determine the posterior plausibility of the null hypothesis and
the alternative hypothesis. We denote the posterior probabil-
ity for the null hypothesis as pBayes(H 0). When, for example,
pBayes(H 0)= 0.9, this means that the plausibility for the null
hypothesis has increased from 0.5 to 0.9, and the plausibility of
the alternative hypothesis has correspondingly decreased from 0.5
to 0.1. We report these posterior probabilities because they address
several problems both with conventional p-values and with prep
(Wagenmakers, 2007; Iverson et al., 2008a,b). Most importantly,
posterior probabilities allow one to directly quantify evidence in
favor of the null hypothesis, instead of only “failing to reject” it. In
the case of our analyses, we perform a one-sample Bayesian t -test
on the difference scores of two measures (during drug and during
placebo), because we want to show the posterior probability that
they are the same.
BEHAVIORAL ANALYSES
Data from three subjects were excluded due to poor behavioral
performance (accuracy<60% in the accuracy condition). Accord-
ingly, we report behavioral data from 17 subjects (8 female; age
µ= 23.0, σ= 3.2). We analyzed subjects’ mean RT and accuracy
using SPSS (PASW Statistics 18.0 for MacOS). Trials in which
there was no response were excluded from the RT calculations.
RT and accuracy rates were entered into separate repeated mea-
sures ANOVAs with within-subjects factors drug (bromocriptine
vs. placebo) and cue (speed vs. accuracy).
Additionally, we analyzed the full correct and incorrect reaction
time distributions per subject using two separate accumulation
models, the DDM and the LBA model. To model the data, trials
with left and right moving dots were collapsed. For each subject, 5
RT quantiles (0.1, 0.3, 0.5, 0.7, 0.9) were computed separately for
correct and error responses. A SIMPLEX minimization routine
(Nelder and Mead, 1965) was used to optimize the fit of the model
predictions’ RT quantiles to those of the behavioral data (Ratcliff
and Tuerlinckx, 2002; Brown and Heathcote, 2008).
To model the data with the DDM, we allowed the threshold and
non-decision time parameters to vary between the speed and the
accuracy condition (e.g., Rinkenauer et al., 2004). The drug and
placebo sessions were fit independently, minimizing the chi-square
statistic.
To model the data with the LBA model, we defined a single
model which allowed the threshold parameter to vary across both
condition and session, and fit this to the data using maximum
likelihood estimation.
We examined drug effects on threshold using a repeated mea-
sures ANOVA with threshold as the dependent measure, and
session and condition as within subject measures. Additionally, we
performed paired sample t -tests and Bayesian t -tests, comparing
speed and accuracy thresholds between drug and placebo.
In addition to testing for an effect of session on behavioral mea-
sures across the group, we also tested whether these effects varied
as a function of subjects’ BIS, BAS, or Barratt scores. We computed
correlations between these three measures and the difference value
of RT and accuracy between the drug and placebo sessions, as
computed separately for both the S and the A trials. This resulted
in 12 comparisons (2 behavioral measures× 2 conditions× 3
personality measures), giving a Bonferroni corrected alpha of
0.05/12= 0.004).
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MRI DATA ACQUISITION
Whole-brain imaging was performed on a 3 T MR scanner
(Magnetom Trio Tim, Siemens Medical Systems, Erlangen, Ger-
many). Functional data were obtained using a gradient-echo
echo-planar scanning sequence with blood oxygenation level-
dependent (BOLD) contrast (30 axial-oblique slices acquired in
interleaved order, repetition time= 2000 ms, echo time= 30 ms,
voxel size= 3.5 mm× 3.5 mm× 3.0 mm, inter slice gap= 0.5 mm,
field of view= 224 mm, flip angle= 80˚). Visual stimuli were pro-
jected on a screen and were viewed through a mirror attached
to the head coil. In addition, a high-resolution T1-weighted MP-
RAGE anatomical scan was obtained from each subject (192 sagit-
tal slices, repetition time= 2300 ms, echo time= 3.03 ms, voxel
size= 1.0 mm× 1.0 mm× 1.0 mm, field of view= 256 mm).
MRI PREPROCESSING
The imaging data from three subjects were excluded due to abrupt
motion artifacts consisting of translations >6 mm or data acqui-
sition problems. Accordingly, we report imaging data from 14
subjects (6 female, age µ= 22.7, σ= 3.3).
Preprocessing was performed using FSL (FMRIB’s Software
Library, version 4.8, www.fmrib.ox.ac.uk/fsl, Smith et al., 2004;
Woolrich et al., 2009). The first four volumes of functional data
were removed to allow T1 equilibrium to set in. Functional
images were corrected for slice time acquisition, pre-whitened,
and realigned to compensate for small head movements (Jenk-
inson et al., 2002). Data were spatially smoothed using a 5 mm
full-width-half-maximum Gaussian kernel, and temporally fil-
tered using a high-pass filter with a cutoff time of 80 s, to correct for
baseline drifts. Functional images were coregistered to the subject’s
T1 structural image, and then normalized to Montreal Neuro-
logical Institute (MNI) space using parameters estimated using
affine transformation based on the structural image (Jenkinson
and Smith, 2001).
MRI ANALYSIS
Functional analysis was performed using FEAT (FMRI Expert
Analysis Tool,Version 5.98, part of FSL). Our first level GLM analy-
sis included regressors for the speed and accuracy cues, which were
convolved with a double-gamma hemodynamic response function
(HRF) and its first-order derivative. The resulting statistical maps
were averaged over the two blocks of the same session.
We performed several higher level analyses using FLAME
(FMRIB’s Local Analysis of Mixed Effects, Beckmann et al., 2003;
Woolrich et al., 2004). These analyses were thresholded at Z = 2.3
on the voxel level, and then thresholded at a cluster level (multiple
comparisons corrected) p value of 0.05. To verify that bromocrip-
tine affected the neural data, we first examined the general effect
of drug on the brain, by computing the difference between the
effect of any cue vs. implicit baseline during the drug and placebo
sessions, regardless of trial type. For the drug and placebo sessions
separately, we computed the difference between activation during
the speed and accuracy cues (S-A contrast). We also computed
covariance analyses for drug and for placebo, using the individual
threshold difference between cues (as estimated by the DDM) as
a covariate. Second, we examined whether the S-A contrast was
modulated by drug, by computing the difference between speed
(drug) and speed (placebo), and the difference between accuracy
(drug) and accuracy (placebo). To allow us to make statistical
inferences regarding activation during drug vs. placebo (Nieuwen-
huis et al., 2011), we directly compared effects of drug on the S-A
contrast in six regions of interest (ROIs) using a paired samples
t -test and Bayesian t -test (Wetzels et al., 2009). We selected these
ROIs based on a priori expectations generated by previous research
(Forstmann et al., 2008), and defined them anatomically. These
six ROIs correspond to the (bilateral) caudate nucleus, putamen,
and pre-SMA. We used the Harvard-Oxford Subcortical Structural
Atlas within FSL to define the caudate nucleus and putamen ROIs,
and anatomical masks ranging from Y = 0 to Y = 30 to define the
pre-SMA ROIs (Johansen-Berg et al., 2004).
Based on the results of these analyses, we needed to get an esti-
mate of the drug effect on the speed network. Directly computing
the difference between drug and placebo based on functional ROIs
from either of these conditions would produce biased statistics,
since it would include those voxels that were significantly active in
one condition, even if this were due to noise (Vul et al., 2009). In
order to gain a qualitative comparison of subthreshold activations
during drug and placebo, we also computed statistical maps with-
out a cluster threshold. In this analysis we used a Z -threshold of
2.3, and no cluster-based threshold.
RESULTS
BEHAVIORAL RESULTS
Analysis of RT showed a main effect of cue [F(1, 16)= 45.2,
p< 0.001]. There was no effect of drug [F(1, 16)= 0.53,
p= 0.475], and no interaction effect of cue× session [F(1,
16)= 1.284, p= 0.247]. Analysis of accuracy showed a main
effect of cue [F(1, 16)= 20.5, p< 0.001]. There was no effect of
session [F(1, 16)= 1.5, p= 0.231] and no interaction effect of
cue× session [F(1, 16)= 0.120, p= 0.734; see Figure 2].
Direct comparison of session effects on RT and accuracy did
not show significant differences, and the result of the Bayesian t -
tests showed evidence in favor of the null hypothesis that drug did
not affect RT and accuracy. There was no effect of session on RT
in the speed [t (16)= 1.6, p= 0.129; pBayes(H 0)= 0.613], or in the
accuracy condition [t (16)= 0.07, p= 0.945; pBayes(H 0)= 0.845].
Similarly, there was no effect of session on accuracy in the speed
[t (16)= 1.07, p= 0.296, pBayes(H 0)= 0.793] or in the accuracy
condition [t (16)= 1.182, p= 0.254, pBayes(H 0)= 0.795].
Analyzing the threshold parameters from the DDM showed
a significant effect of condition [F(1, 16)= 27.5, p< 0.001], but
no significant effect of session [F(1, 16)= 0.0955, p= 0.76], and
no interaction effect [F(1, 16)= 0.82, p= 0.38]. There was a sig-
nificant difference between the speed and accuracy condition,
both during placebo [t (16)= 4.31, p< 0.001], and during drug
[t (16)= 3.84, p= 0.0014].
Direct comparison of session effects on threshold did not show
significant differences, and the result of the Bayesian t -tests showed
evidence in favor of the null hypothesis that drug did not affect
thresholds. There was no effect of session on threshold in the accu-
racy [t (16)=−0.71, p= 0.49; pBayes(H 0)= 0.81] or in the speed
condition [t (16)= 0.52, p= 0.61; pBayes(H 0)= 0.83].
Analyzing the threshold parameters from the LBA model
showed a significant effect of condition [F(1, 16)= 51.5,
p< 0.001], but no significant effect of session [F(1, 16)= 0.120,
p= 0.734], and no interaction effect [F(1, 16)= 0.025, p= 0.877].
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FIGURE 2 | Summary statistics. Mean reaction times and accuracy rates across the two sessions (drug and placebo) and the two cues (speed and accuracy).
Error bars indicate the standard error of the mean.
FIGURE 3 | Model fits and parameter estimates. This figure shows the
vincentized behavioral data and model fits (top) and the threshold estimates
per experimental condition (bottom) of the LBA model (left) and the DDM
(right). As the reaction time distributions in the top figure are plotted by their
probabilities, the error distributions are shown on the left side of each plot,
while the correct distributions are shown on the right side.
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There was a significant difference between the speed and accu-
racy condition, both during placebo [t (16)= 6.398, p< 0.001],
and during drug [t (16)= 6.945, p< 0.001].
Direct comparison of session effects on threshold did not show
significant differences, and the result of the Bayesian t -tests showed
evidence in favor of the null hypothesis that drug did not affect
thresholds. There was no effect of session on threshold in the accu-
racy[(t (16)=−0.12, p= 0.91; pBayes(H 0)= 0.84] or in the speed
condition [t (16)=−1.0, p= 0.34; pBayes(H 0)= 0.77].
The DDM and LBA model fits, as well as the corresponding
parameter estimates are shown in Figure 3.
The correlations between drug effect on behavior and per-
sonality questionnaires did not yield significant activations even
before correcting for multiple comparisons. The highest corre-
lation found in these 12 analyses was R(17)= 0.482, p= 0.051
between subjects’ BIS score and the drug effect on their accu-
racy in the speed condition. Note that the Bonferroni correction
prescribes an alpha value of 0.05/12= 0.004.
fMRI RESULTS
Our general analysis of the effect of drug on cue (regardless of
cue type) vs. implicit baseline revealed significantly activated clus-
ters in the bilateral midbrain (including regions of the brainstem,
pallidum, thalamus, and subthalamic nucleus), in the left lateral
occipital cortex (including area MT) and in the right inferior
frontal gyrus.
Our initial contrast comparing S-A trials during placebo
revealed increased activation in the bilateral striatum, the bilat-
eral pre-SMA, bilateral occipital poles, the right IPS, and the right
posterior cingulate cortex. During drug, significant activation was
found only in the occipital pole (see Figure 4A; Table 1). However,
the analysis of the interaction between session and condition did
not yield significant activations at the whole-brain level.
Direct comparisons of extracted activation levels from cau-
date nucleus, putamen, and pre-SMA ROIs revealed no significant
differences between the drug and the placebo session [left cau-
date nucleus(t (13)= 1.096, p= 0.293; pBayes(H 0)= 0.74], right
caudate nucleus[t (13)= 1.293, p= 0.219; pBayes(H 0)= 0.70], left
putamen [t (13)= 1.358,p= 0.198;pBayes(H 0)= 0.68], right puta-
men [t (13)= 1.211, p= 0.247; pBayes(H 0)= 0.72], left pre-SMA
[t (13)= 0.842, p= 0.415; pBayes(H 0)= 0.78], right pre-SMA
[t (13)= 1.216, p= 0.246; pBayes(H 0)= 0.72]. Our voxel thresh-
olded qualitative comparison (see Figure 4B) illustrates the pres-
ence of subthreshold activation during drug, in the regions that
were significantly activated during placebo. The covariate analyses
did not yield significant activations in either the drug or placebo
conditions.
DISCUSSION
In this experiment, we have investigated the effect of bromocrip-
tine on speed–accuracy tradeoff. Contrary to our hypothesis, we
have found that bromocriptine does not alter decision thresholds
in perceptual decisions. There are several possible explanations
why we did not find such an effect. We can rule out the expla-
nation that our pharmacological manipulation was unsuccessful,
because we do find effects of bromocriptine on neural activa-
tions in our main contrast of task. Also, the same dosage and
A B
FIGURE 4 | fMRI results. Results of the fMRI analyses showing the
speed–accuracy contrast during placebo (yellow) and during drug (blue). (A)
Cluster thresholded with a voxel thresholded of Z =2.3, and a cluster
threshold of p=0.05. (B) Voxel thresholded results, with a voxel threshold
of Z =2.3 and no cluster threshold. The statistical maps are overlaid on
Montreal Neurological Institute (MNI) T1 anatomical scans with a 2 mm
resolution.
Table 1 | fMRI results.
Region Cluster size Cluster p x y z
MAIN EFFECT OF DRUG ON CUE
Bilateral brainstem 533 0.00389 0 −15 −8
Right inferior frontal gyrus 459 0.0102 49 24 12
Left lateral occipital cortex 391 0.0257 −44 −70 13
SPEED–ACCURACY (PLACEBO)
Bilateral pre-SMA 3412 1.15e–11 8 7 51
Bilateral striatum 3055 9.87e–11 −2 −3 6
Right occipital pole 1388 7.33e–6 −29 −93 3
Left occipital pole 913 0.000381 29 −97 2
Posterior cingulate 538 0.0145 1 −24 29
Right intraparietal sulcus 448 0.0384 60 −45 39
SPEED–ACCURACY (DRUG)
Left occipital pole 983 0.00115 26 −98 1
Right occipital pole 836 0.00351 −25 −99 3
Significantly activated clusters (cluster-corrected p<0.05) in the speed–accuracy
contrast during placebo and during drug, based on voxels that exceed a Z-
threshold of 2.3. The cluster size is in voxels. Coordinates correspond to the
spatial center of gravity of the Z-values in the cluster, represented in MNI space.
pre-SMA, pre-supplementary motor area.
timing schema have been successfully employed to show signifi-
cant effects in numerous other studies (Cools et al., 2007, 2009;
Van Holstein et al., 2011; Van der Schaaf et al., in preparation; Van
Schouwenburg et al., in submission). However, we cannot rule out
that a higher dose of bromocriptine or a different drug might still
affect SAT, for instance because SAT could be mainly driven by
D1 receptors, or be sensitive to dopamine precursors or reuptake
inhibitors, but not to direct agonists.
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The most obvious explanation for our findings is simply that,
contrary to our hypothesis, dopamine does not regulate SAT. This
interpretation is supported by our Bayesian analyses, which sup-
port the null hypothesis that bromocriptine does not affect mean
RT and accuracy. Bayesian analyses on the threshold parameters
as determined by the DDM and LBA model also support the null
hypothesis. However, we should be cautious to draw general con-
clusions about the role of dopamine based on just these findings
using bromocriptine. It is still possible that dopamine does play
a role in SAT, but that the relevant aspect of the dopaminergic
system is not affected by bromocriptine. This could be due to the
receptor specificity of bromocriptine, or due to selective effects
of tonic vs. phasic dopaminergic signaling. It could also be the
case that decision threshold is less sensitive to this manipula-
tion, requiring a higher dose to be effective. Another possibility
is that the postsynaptic effect of bromocriptine is counteracted
by its effect on presynaptic autoreceptors, which might decrease
the amount of dopamine released into the synapse (Laakso et al.,
2005; Stelzel et al., 2010). Further experiments using dopamine
reuptake inhibitors or precursors should provide further insight
into these issues. A final explanation is that bromocriptine has
different effects based on individual differences in the subjects’
dopaminergic systems, which together occlude any group effects
(Cools and D’Esposito, 2011). While such an effect was not found
when examined as a function of working memory or impulsivity,
our sample size is insufficient to investigate individual differences
based on genetic polymorphisms. This possibility warrants further
investigation.
In our fMRI data, we have replicated and expanded the pre-
vious findings of Forstmann et al. (2008). We have confirmed
that speeded decision making is associated with enhanced neural
activation in the striatum and pre-SMA, as well as in the IPS, occip-
ital pole, and posterior cingulate cortex. The observation that the
occipital pole is also affected by speed cues is interesting, as it
shows top-down effects on early perceptual processing regions,
which take place before the target stimulus is presented. Effects
of drift and threshold changes with SAT on activity in area V1
have recently been discovered (Ho et al., 2012). Understanding
our fMRI data in relation to drug is not straightforward. At
first glance, the cluster-corrected whole-brain maps (Figure 4A)
suggest an effect in placebo and not in drug, but the differ-
ence between the two maps is not significant. This means that
although one effect differs significantly from 0 and the other does
not, the difference between the two cannot be interpreted sta-
tistically (Nieuwenhuis et al., 2011). Direct comparisons based
on the activated regions would also not be a valid statistical
analysis, since only including those voxels that show significant
activation in one condition introduces a bias toward a significant
difference between the conditions (Vul et al., 2009). Neither the
whole-brain interaction between session and condition, nor the
anatomical ROI analyses show a significant difference between
drug and placebo, and Bayesian analyses show the evidence to be
in favor of the null hypothesis. The absence of a difference is can be
explained by the qualitative comparison of the non-thresholded
images (Figure 4B). These show that there is subthreshold acti-
vation during drug in the regions that are significantly active
during placebo. Taken together, our imaging findings suggest that
there is no effect of bromocriptine on the effect of cue on the
brain.
To summarize, we have replicated the finding that striatum and
pre-SMA are active when preparing fast decisions. We have found
that bromocriptine does not alter subjects’ decision threshold, and
that it does not change the activation of the known speed related
network in the brain.
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